A lab study described an “inhaled living medicine” approach: engineered bacteria designed to disrupt ventilator-tube biofilms reduced Pseudomonas aeruginosa biofilm thickness in pigs without evidence of tissue damage. The preclinical result used nebulization to deliver the agent and demonstrated an approximate 40% reduction in biofilm thickness compared with baseline measurements. Separately, researchers reported that phenolic acid (p-coumaric acid) restored imipenem efficacy against extensively drug-resistant Acinetobacter baumannii in laboratory models, indicating a potential adjuvant strategy to reverse antibiotic tolerance. Both developments underscore near-term innovation targets in antimicrobial resistance—either by physically disrupting biofilm architecture or by re-sensitizing pathogens to existing antibiotics.